Where does Quark Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Quark Pharmaceuticals, Inc. ranks #10,731 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Quark Pharmaceuticals, Inc. hold?

Quark Pharmaceuticals, Inc. holds 29 US utility patents granted between 2015 and 2020, spanning 8 technology areas.

What is Quark Pharmaceuticals, Inc.'s Innovation Score?

Quark Pharmaceuticals, Inc. has an Innovation Score of 30.5 out of 100 (34th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Quark Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Quark Pharmaceuticals, Inc.'s recent grant velocity is -93% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Quark Pharmaceuticals, Inc.'s patents?

Quark Pharmaceuticals, Inc.'s patents average 14.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Quark Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Quark Pharmaceuticals, Inc.

Q: What technology areas does Quark Pharmaceuticals, Inc. focus on?

Quark Pharmaceuticals, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 28 patents, ranking #381 of 4,144 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 29 granted patents across 8 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Quark ranks #10,731 of 49,997 tracked US assignees by granted-patent volume, with 29 patents across 8 technology areas.

#10,731
of 49,997 US assignees by volume: 34th percentile
by Innovation Score (30.5/100): 14.6
avg claims per patent: -93%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10731 · US Corporation #10,731 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 29 grants
UPPER-Q #10,731/49,997
PHOTO-FINISH Palo Alto Investors
CPC-NARROW C12N · 8 areas
INNOV-THIN 30.5/100
CLAIMS-RICH 14.6 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -93% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Palo Alto Investors LP (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Quark’s 30.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.7 pts (38%) Velocity 0.0 pts (0%) Breadth 10.0 pts (33%) Claim depth 8.7 pts (29%)

Qualcomm Incorporated · highest

85
Worldwide Creations · near

30
Amobee · near

30
Precor Incorporated · near

30
Quark Pharmaceuticals · this assignee

30
State Atomic Energy… · near

30
3D Lighting… · lowest

7

What this shows Quark's Innovation Score is 30.5/100 (34th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Quark?

Each dot is one of Quark’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Quark’s own 14.6 claims/patent is at or below the 15.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Quark vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Quark's grants concentrate

Quark Pharmaceuticals, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 96.6% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2015 (7 grants) versus a trough of 2 in 2019. By volume, Quark sits between Palo Alto Investors LP and Resource Consortium Limited, LLC.

Palo Alto Investo…

29
Phazr

29
Prüftechnik Diete…

29
Qingdao Haier AIR…

29
Quickstep

29
Radiant Innovation

29
Raymx Microelectr…

29
Resource Consorti…

29
Quark Pharmaceuti… ◀

29

What this shows Quark holds 29 patents at rank #10,730, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Quark

By rank, the assignees closest to #10,730 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Quark's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Quark, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Quark ranks #381 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (30 here).

Precor Incorporated 30 Amobee, Inc. 30 Worldwide Creations, LLC 30 State Atomic Energy Corporation “ROSATOM” Acts on Behalf of the Russian Federation 30

Quark's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 34th percentile higher than 34% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Quark Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	24.1%
2016	7	24.1%
2017	7	24.1%
2018	4	13.8%
2019	2	6.9%
2020	2	6.9%

Which technologies does Quark Pharmaceuticals, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 28

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 25

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

C12Y - Enzymes 5

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C07K - Peptides 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Quark Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Quark Pharmaceuticals, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 96.6% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #10,731 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Quark Pharmaceuticals, Inc. against Palo Alto Investors LP, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.